BioCryst Pharma (BCRX)
9.96
-0.13 (1.29%)
Upcoming Events
Latest Headlines
Japan approves BioCryst's Orladeyo for children ages 2 to 12 with HAE
August 25, 2026 7:02 AM - StreetInsider
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
August 25, 2026 7:01 AM - Globe NewsWire
Form SCHEDULE 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P.
August 14, 2026 4:48 PM - SEC Filing
Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: STATE STREET CORP
August 7, 2026 8:56 AM - SEC Filing
BioCryst Pharma (BCRX) PT Lowered to $13 at RBC Capital
August 6, 2026 6:43 AM - StreetInsider
Form S-8 BIOCRYST PHARMACEUTICALS
August 5, 2026 4:25 PM - SEC Filing
Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30
August 5, 2026 4:05 PM - SEC Filing
BioCryst Pharma (BCRX) PT Lowered to $20 at Wedbush
August 5, 2026 12:40 PM - StreetInsider
BioCryst Pharma (BCRX) Tops Q2 EPS by 14c
August 5, 2026 7:22 AM - StreetInsider
Form 8-K BIOCRYST PHARMACEUTICALS For: Aug 05
August 5, 2026 7:03 AM - SEC Filing
BioCryst Reports Second Quarter 2026 Financial Results
August 5, 2026 7:00 AM - Globe NewsWire
Form 8-K/A BIOCRYST PHARMACEUTICALS For: Jun 25
August 4, 2026 7:01 AM - SEC Filing
BioCryst to Report Second Quarter 2026 Financial Results on August 5
July 22, 2026 7:00 AM - Globe NewsWire
BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens on Orladeyo Potential
July 17, 2026 5:10 AM - StreetInsider
BioCryst names David Jenkins as chief scientific officer
July 15, 2026 7:01 AM - StreetInsider
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
July 15, 2026 7:00 AM - StreetInsider
JPMorgan Resumes BioCryst Pharma (BCRX) at Neutral
July 13, 2026 3:15 AM - StreetInsider
BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026 7:00 AM - Globe NewsWire
BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies
June 30, 2026 4:42 AM - StreetInsider
Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25
June 29, 2026 7:07 AM - SEC Filing
BioCryst to close Birmingham lab and shift to external R&D model
June 29, 2026 7:00 AM - StreetInsider
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
June 29, 2026 7:00 AM - StreetInsider
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Milne Jill C.
June 15, 2026 4:32 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Galson Steven K
June 15, 2026 4:31 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: LEVIN ALAN G
June 15, 2026 4:29 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Frank Steven
June 15, 2026 4:16 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: SANDERS MACHELLE
June 15, 2026 4:15 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: MILANO VINCENT
June 15, 2026 4:12 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Stonehouse Jon P
June 15, 2026 4:10 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: McKee Amy E
June 15, 2026 4:08 PM - SEC Filing
Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: HEGGIE THERESA
June 15, 2026 4:06 PM - SEC Filing
Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 11
June 12, 2026 4:11 PM - SEC Filing
BioCryst presents HAE treatment data at European allergy meeting
June 12, 2026 7:00 AM - StreetInsider
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
June 12, 2026 7:00 AM - Globe NewsWire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 9, 2026 4:05 PM - Globe NewsWire
Full Article List
